National Institute for Clinical Excellence (NICE)
MidCity Place
71 High Holborn
London
WC1V 6NA
United Kingdom
Tel: 44-0-20-7067-5800
Fax: 44-0-20-7067-5801
Website: http://www.nice.org.uk/
Email: nice@nice.nhs.uk
169 articles about National Institute for Clinical Excellence (NICE)
-
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
12/4/2023
CEL-SCI Corporation announced that the British National Institute for Health and Care Excellence has selected Multikine* to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck in the UK.
-
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
10/12/2023
PROCEPT BioRobotics® Corporation, a surgical robotics global leader, is pleased to announce that the National Institute for Health and Care Excellence has bestowed its strongest endorsement, the "standard arrangements" recommendation, on Aquablation® therapy for the treatment of benign prostatic hyperplasia.
-
National Institute for Clinical Excellence Publishes Medical Innovation Briefing Appraising QbTest
3/9/2023
The National Institute for Clinical Excellence, a UK government-funded, non-departmental public body that aims to establish guidelines for clinical best practice, recognizes QbTest in its MedTech Innovation Briefing, MIB318.
-
Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®▼ (fremanezumab)
3/12/2020
Teva Pharmaceutical Europe BV an affiliate of Teva Pharmaceutical Industries Ltd. announced that the National Institute for Health and Care Excellence has recommended AJOVY in its Final Appraisal Document for the prevention of migraine in adults with chronic migraine.
-
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
12/19/2018
Only test recommended based on its ability to predict chemotherapy benefit
-
Augmenix Release: NICE Announces Interventional Procedure Guidance Supporting Use Of Hydrogel Spacer In Treatment Of Prostate Cancer In The UK
8/30/2017
-
Roche’s Tecentriq Hits Trouble with NICE in Bladder Cancer
8/3/2017
-
Teva Release: NICE Recommends CINQAERO (Reslizumab) For The Treatment Of Severe Eosinophilic Asthma
7/20/2017
-
Alexion Reaches Funding Agreement With NICE And National Health Service England For Strensiq (Asfotase Alfa) For Patients With Pediatric-Onset Hypophosphatasia (HPP)
7/5/2017
-
Interrad Medical Release: SecurAcath Receives NICE Recommendation: Highlights Massive Cost Savings From Improved Catheter Securement
6/6/2017
-
SI-BONE Announces Published Guidance Recommendation For Minimally Invasive SI Joint Fusion From The SI-BONE
4/7/2017
-
NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife Battery Technology For Treatment Of Heart Failure
3/17/2017
-
Intercept Pharma Release: NICE Recommends Ocaliva® (Obeticholic Acid) For The Treatment Of Patients With Primary Biliary Cholangitis In England, Wales And Northern Ireland
3/2/2017
-
NICE Guidance Recommends HeartFlow FFRct Analysis To Help Determine Cause Of Stable Chest Pain In Patients
2/13/2017
-
Entellus Medical Release: NIH And NICE Provides Positive Guidance For Use Of The Xpress Multi-Sinus Dilation System For Treating Chronic Sinusitis
12/13/2016
-
CytoSorbents Release: CytoSorb Selected For NICE MedTech Innovation Briefing In The United Kingdom
12/1/2016
-
NICE U-Turns and Backs Approval of Roche's Perjeta for HER2-Positive Breast Cancer
11/22/2016
-
Vascular Insights Release: NICE Issues Approval Via Interventional Procedure Guidance IPG557 For Endovenous Mechanochemical Ablation For Varicose Veins In The United Kingdom
7/25/2016
-
Vascular Insights Release: National Institute For Health And Care Excellence (NICE) Issues Approval Via Interventional Procedure Guidance IPG557 For Endovenous Mechanochemical Ablation For Varicose Veins In The United Kingdom
7/14/2016
-
PTC Therapeutics Release: National Institute for Clinical Excellence (NICE) Recommends Translarna (Ataluren) For The Treatment Of Patients With Nonsense Mutation Duchenne Muscular Dystrophy In England
4/15/2016